High Tide Inc. (HITI) Announces Fourth Quarter Loss, Beats Revenue Estimates
High Tide Inc. (HITI) exited with a quarterly loss of $0.06 per share against the Zacks consensus estimate of a loss of $0.05. That compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents a profit surprise of -20%. A quarter ago, this company was expected to post a loss of $0.07 per share when it actually produced a loss of $0.03, delivering a surprise of 57.14%.
In the past four quarters, the company has exceeded consensus EPS estimates only once.
High tide inc.
The sustainability of the immediate stock price movement based on recently released numbers and future earnings forecasts will primarily depend on management’s comments on the earnings call.
Shares of High Tide Inc. have gained about 10.4% year-to-date compared to the S&P 500’s 6% gain.
What’s next for High Tide Inc.
While High Tide Inc. has outperformed the market so far this year, the question on investors’ minds is: what’s next for the stock?
There are no easy answers to this key question, but one reliable metric that can help investors answer it is the company’s earnings outlook. This includes not only the current consensus earnings expectations for the upcoming quarter(s), but also how those expectations have changed recently.
Empirical research shows a strong correlation between short-term stock movements and trends in earnings estimate revisions. Investors can track these revisions on their own or rely on a proven scoring tool like Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Prior to this earnings release, the trend in estimate revisions for High Tide Inc. Mixed. While the magnitude and direction of estimate revisions may change following the release of the company’s earnings report, the current situation translates into a No. 3 (hold) Zacks ranking for the stock. Thus, the shares should move in line with the market in the near future. You can see the full list of today’s Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how the estimates for the next few quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.05 on $80.33 million in revenue for the upcoming quarter and -$0.14 on $353.13 million in revenue for the current fiscal year .
Investors should be aware that the outlook for the sector can also have a significant impact on stock performance. In terms of Zacks industry rankings, Medical – Products is currently in the bottom 43% of over 250 Zacks industries. Our research shows that the top 50% of industries ranked by Zacks outperform the bottom 50% by a factor of more than 2 to 1.
Another stock in the same sector, SurModics (SRDX), has not yet released its results for the quarter ending December 2022. The results are expected to be released on February 6.
This drug delivery technology company is expected to post a quarterly loss of $0.64 per share in its upcoming report, representing a year-over-year change of -392.3%. The consensus EPS estimate for the quarter remained unchanged for the past 30 days.
SurModics revenue is expected to be $24.19 million, up 5.2% from the prior year quarter.
Just Released: Zacks Top 10 Stocks for 2023
In addition to the investment ideas discussed above, would you like to know our top 10 picks for 2023?
From its creation in 2012 until November, the Zacks Top 10 Stocks portfolio tripled the market, gaining an impressive +884.5% versus +287.4% for the S&P 500. Our research director has now combed through 4,000 companies covered by the Zacks ranking and selected the top 10 tickers to buy and hold in 2023. Don’t miss your chance to always be among the first to participate in these newly released stocks.
See the new Top 10 stocks >>
Want the latest recommendations from Zacks Investment Research? Today you can download 7 best stocks for the next 30 days. Click to get this free report
High Tide Inc. (HITI): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
To read this article on Zacks.com, click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.